About this Event

For life science companies, valuing an early stage product or pipeline is uniquely challenging. It requires detailed analysis and thoughtful forecasting of the potential of your product. Understanding the phase-by-phase risk your company will face is essential to determining the valuation of your early stage product or pipeline.

In this session, we will knit these key elements together to better understand valuations today and through each valuation inflection point.